Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Inventory (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Inventory for 16 consecutive years, with $102.6 million as the latest value for Q1 2026.

  • Quarterly Inventory rose 47.14% to $102.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $102.6 million through Jan 2026, up 47.14% year-over-year, with the annual reading at $102.6 million for FY2026, 47.14% up from the prior year.
  • Inventory for Q1 2026 was $102.6 million at Usana Health Sciences, up from $90.8 million in the prior quarter.
  • The five-year high for Inventory was $102.6 million in Q1 2026, with the low at $60.1 million in Q3 2023.
  • Average Inventory over 5 years is $74.7 million, with a median of $67.3 million recorded in 2022.
  • The sharpest move saw Inventory crashed 33.91% in 2023, then skyrocketed 47.14% in 2026.
  • Over 5 years, Inventory stood at $67.1 million in 2022, then fell by 8.4% to $61.5 million in 2023, then increased by 13.48% to $69.7 million in 2024, then skyrocketed by 30.18% to $90.8 million in 2025, then grew by 13.03% to $102.6 million in 2026.
  • According to Business Quant data, Inventory over the past three periods came in at $102.6 million, $90.8 million, and $83.3 million for Q1 2026, Q3 2025, and Q2 2025 respectively.